A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease

Table 1 Baseline Characteristics

Characteristic	Calcium acetate (N = 46)	Placebo (N = 64)	P-value
Age (years)	63.2 ± 11.7	62.2 ± 14.2	0.69
Gender (female)	23 (50%)	29 (45.3%)	0.63
Race (white)	33 (71.7%)	54 (84.4%)	0.34
Diabetes	31 (67.4%)	49 (76.6%)	0.29
Weight (Kg)	82.9 ± 23.2	80.8 ± 25.6	0.65
Serum phosphorus (mg/dL)	5.1 ± 1.2	5.1 ± 1.1	0.76
Serum calcium, corrected (mg/dL)	9.1 ± 0.7	9.1 ± 0.6	0.97
Intact parathyroid hormone (pg/mL)¹	253 ± 213	322 ± 267	0.16
Serum albumin (mg/dL)	3.6 ± 0.5	3.5 ± 0.5	0.56
Serum bicarbonate (mEq/L)	22.6 ± 3.9	21.9 ± 3.7	0.33
Estimated glomerular filtration rate (mL/min/1.73 m²)	17.3 ± 5.6	16.4 ± 6.2	0.43

¹Available in 45 and 56 patients in the calcium acetate and placebo groups, respectively.

ISSN: 1471-2369